Pharming Group N.V. Files 6-K with Press Release
Ticker: PHAR · Form: 6-K · Filed: 2024-10-10T00:00:00.000Z
Sentiment: neutral
Topics: disclosure, press-release
TL;DR
Pharming Group N.V. dropped a 6-K with a press release today, check for updates.
AI Summary
Pharming Group N.V. filed a Form 6-K on October 10, 2024, to furnish a press release dated the same day as Exhibit 99.1. The filing does not contain specific financial figures or operational updates within the provided text, but indicates the release of new information by the company.
Why It Matters
This filing signals that Pharming Group N.V. is releasing new information to the public, which could impact its stock price and investor decisions.
Risk Assessment
Risk Level: low — The filing is a standard disclosure of a press release and does not contain inherently risky information.
Key Players & Entities
- Pharming Group N.V. (company) — Registrant
- October 10, 2024 (date) — Filing and Press Release Date
- 001-39822 (other) — SEC File Number
- Exhibit 99.1 (other) — Attached Document
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to furnish a press release, dated October 10, 2024, as Exhibit 99.1.
What is the SEC file number for Pharming Group N.V.?
The SEC file number for Pharming Group N.V. is 001-39822.
On what date was the press release furnished with this filing?
The press release was furnished on October 10, 2024.
Does Pharming Group N.V. file annual reports under Form 20-F or 40-F?
Pharming Group N.V. files annual reports under Form 20-F, as indicated by the checkmark next to it.
What is the principal executive office address for Pharming Group N.V.?
The principal executive offices are located at Darwinweg 24, 2333 CR Leiden, The Netherlands.
From the Filing
0001828316-24-000033.txt : 20241010 0001828316-24-000033.hdr.sgml : 20241010 20241010060604 ACCESSION NUMBER: 0001828316-24-000033 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20241010 FILED AS OF DATE: 20241010 DATE AS OF CHANGE: 20241010 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Pharming Group N.V. CENTRAL INDEX KEY: 0001828316 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: P7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39822 FILM NUMBER: 241363738 BUSINESS ADDRESS: STREET 1: DARWINWEG 24 CITY: LEIDEN STATE: P7 ZIP: 2333 CR BUSINESS PHONE: 31 (0)71 5247 400 MAIL ADDRESS: STREET 1: DARWINWEG 24 CITY: LEIDEN STATE: P7 ZIP: 2333 CR FORMER COMPANY: FORMER CONFORMED NAME: Pharming Group Group N.V. DATE OF NAME CHANGE: 20201014 6-K 1 pharminggroupannouncesstrt.htm 6-K Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October Commission File Number: 001-39822 Pharming Group N.V. (Exact Name of Registrant as Specified in Its Charter) Darwinweg 24 2333 CR Leiden The Netherlands (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐ Furnished as Exhibit 99.1 to this Report on Form 6-K is a press release of Pharming Group N.V., or the Company, dated October 10, 2024. EXHIBIT INDEX Exhibit No. Description 99.1 Pharming Group announces start of Phase II clinical trial of leniolisib for primary immunodeficiencies (PIDs) with immune dysregulation SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Pharming Group N.V. By: /s/ Sijmen de Vries Name: Sijmen de Vries Title: CEO Date: October 10, 2024 Pharming Group announces start of Phase II clinical trial of leniolisib for primary immunodeficiencies (PIDs) with immune dysregulation Proof of concept clinical trial will evaluate leniolisib in PIDs with immune dysregulation linked to altered PI3Kẟ signaling in lymphocytes PIDs to include ALPS-FAS, CTLA4 haploinsufficiency, NFKB1 haploinsufficiency and PTEN deficiency, with prevalence approximately five times that of APDS Clinical trial being conducted at the National Institutes of Health (NIH) Leiden, the Netherlands, October 10, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) : Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces the start of a Phase II, proof of concept, clinical trial evaluating leniolisib in primary immunodeficiencies (PIDs) with immune dysregulation linked to altered PI3Kẟ signaling in lymphocytes. The clinical trial is open for enrollment and will include PID patients with ALPS-FAS, CTLA4 haploinsufficiency, NFKB1 haploinsufficiency and PTEN deficiency, among others. These PID patients exhibit altered PI3Kẟ signaling in lymphocytes and likewise display similar clinical phenotypes to activated phosphoinositide 3-kinase delta syndrome (APDS) patients. Epidemiology suggests a prevalence of approximately seven patients per million in this targeted PID population, compared to one to two patients per million